Beryl Drugs Ltd.

The trailing twelve month (TTM) PB ratio of Beryl Drugs Ltd. is 1.35 as of March 19, 2025. The PB ratio measures the market capitalization of the company relative to it’s book value (carrying value on the balance sheet) as of last reported period.

Beryl Drugs Ltd. reported an ROE of 9.05% for the last reported financial year on a consolidated account basis. Return on Equity (ROE) reflects how efficiently the company is able to generate profit as a percent of their equity financing.

Shareholding pattern gives insights on the concentration of holdings towards various groups of investors. As of last reported quarter for Beryl Drugs Ltd., Promoter held 26.4%, and the public held 73.6% of the total shares.

You can easily buy shares of Beryl Drugs Ltd. online through Share.Market. If you are an existing user, login to your account, else follow the process to create your own Demat and Trading account in a few easy steps.

The fair value of Beryl Drugs Ltd. is an estimated price at which buyers and sellers would freely trade their shares. The various ways to determine the fair value of an asset include looking at recent market transactions for similar assets, estimating its expected earnings or the cost of replacing it.